TITLE

Síndrome metabólico en menopausia: implicaciones de la terapia hormonal

AUTHOR(S)
Tabares-Trujillo, María Katherine; Aguilera-Pérez, Jesús Rafael; Velázquez-Valassi, Beatriz; Garza-Ríos, Pablo; Citlalli Angulo-Torres, Lizbeth; García-Ruiz, Rosalía
PUB. DATE
January 2012
SOURCE
Perinatologia y Reproduccion Humana;ene-mar2012, Vol. 26 Issue 1, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: The incidence of cardiovascular disease and metabolic syndrome during the menopause is around 35%. The objective of this study was to establish the relation between anthropometric and biochemical values in those patients with metabolic syndrome with and without hormone replacement therapy during menopause. Methods: A retrospective cohort study with case analysis of the Coordination of Peri and Postmenopause at the Instituto Nacional de Perinatología Isidro Espinosa de los Reyes during the period between 1998 and 2009; the study included those patients with diagnosis of metabolic syndrome. The variables analyzed were: a) anthropometric, b) biochemical indicators and c) blood pressure levels, divided in two groups: patients with hormone replacement therapy (Group I) and patients without hormonal therapy (Group II). The statistical analysis were performed depending on the variable, with chi-square, Student t test and OR, CI (95%). Results: 310 cases were included: Group I, 121 cases and Group II 189 cases. There were no statistically significant differences on anthropometric and biochemical indicators, but significant differences in cholesterol (p=0.024) and diastolic blood pressure levels, were found (p <0.001) in patients receiving hormone replacement therapy. Group II had an OR 5.27, CI 95% (2-13.87) for diastolic blood pressure> 90 mmHg. Conclusions: Patients with metabolic syndrome without hormone replacement therapy have an increased risk for diastolic blood pressure > 90 mmHg and a tendency to maintain higher cholesterol levels and increasing the risk of developing cardiovascular disease, although research on the different risk factors, and the implications of hormone therapy, are still insufficient to recognize the scale of the problem in the climacteric woman.
ACCESSION #
91533939

 

Related Articles

  • Hormone replacement therapy (HRT) with drospirenone offers the additional benefit of blood pressure reduction in postmenopausal women.  // Drugs & Therapy Perspectives;Feb2008, Vol. 24 Issue 2, p12 

    The risk of cardiovascular (CV) events in postmenopausal women increases with the use of hormone replacement therapy. Drospirenone, a unique synthetic progestogen, is effective in treating menopausal symptoms and also has potent antimineralocorticoid effects that counteract the sodium- and...

  • Hormone Replacement Therapy and Longitudinal Changes in Blood Pressure in Postmenopausal Women. Scuteri, Angelo; Bos, Angelo J.G.; Brant, Larry J.; Talbot, Laura; Lakatta, Edward G.; Fleg, Jerome L. // Annals of Internal Medicine;8/21/2001, Vol. 135 Issue 4, p229 

    Investigates the association between hormone replacement therapy (HRT) and longitudinal changes in blood pressure in postmenopausal women. Similarity of systolic blood pressure at baseline between HRT users and nonusers; Independence of systolic blood pressure on cardiovascular risk factors,...

  • Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: Influence of hormone replacement therapy. Fernández-Vega, Francisco; Abellán, José; Vegazo, Onofre; De Vinuesa, Soledad García; Rodríguez, José Carlos; Maceira, Benito; De Castro, Saturnino Sanz; Nicolás, Roberto Robles; Luño, José // Kidney International Supplement;Dec2002, Issue 82, p36 

    Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: Influence of hormone replacement. Background. Hypertension is twice as common in postmenopausal than in premenopausal women. This study evaluated the effectiveness of a blockade of the...

  • The HERS trial results: Paradigms lost? Herrington, David M. // Annals of Internal Medicine;09/21/99, Vol. 131 Issue 6, p463 

    Discusses the findings of the Heart and Estrogen/progestin Replacement Study (HERS) conducted in the United States to examine the effects of postmenopausal hormone replacement therapy on the risk for cardiovascular disease. Overall null effect of estrogen plus prostegin therapy; Possible causes...

  • Postmenopausal hormone replacement therapy and cardiovascular mortality in Central-Eastern Europe. Acs, Nandor; Vajo, Zoltan; Acs, N; Vajo, Z; Miklos, Z; Siklósi, G; Paulin, F; Szekacs, B // Journals of Gerontology Series A: Biological Sciences & Medical ;Mar2000, Vol. 55 Issue 3, pM160 

    Background: The leading cause of death among elderly women is cardiovascular (CV) disease in the United States and in Western Europe as well. The protective effect of postmenopausal hormone replacement therapy (HRT) on coronary heart disease has been verified in epidemiologic...

  • Hormone Therapy: A Prescription for Replacement. Mitchell, Penni // Herizons;Winter2003, Vol. 16 Issue 3, p29 

    Focuses on doctors' recommendation of hormone replacement therapy (HRT) for menopausal women since the 1970s and the discovery of its side-effects, as of July 2002. Promotion of estrogen replacement by U.S.-based doctors during the 1960s; Development of formula of standard HRT during the 1970s;...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;1/12/2008, Issue 1184, p2 

    This section offers world news briefs on the pharmaceutical industry. The name of the Canadian Adverse Drug Reaction Monitoring Program has been changed to Canada Vigilance. A meta-analysis conducted by the American Association of Clinical Endocrinologists (AACE) found that young women in early...

  • New HRT approved. Mauldin, Robert K. // Modern Medicine;Jul99, Vol. 67 Issue 7, p55 

    Reports the approval of the United States Food and Drug Administration (FDA) on the use of synthetic conjugated estrogens A (Cenestin) for hormone replacement therapy. Mechanism of action of the drug; Adverse effect of the drug.

  • Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Cannoletta, Marianna; Cagnacci, Angelo // International Journal of Women's Health;2014, Vol. 6, p745 

    The rate of hypertension increases after menopause. Whether estrogen and progesterone deficiency associated with menopause play a role in determining a worst blood pressure (BP) control is still controversial. Also, studies dealing with the administration of estrogens or hormone therapy (HT)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics